Merrimack Pharmaceuticals

Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. Such an approach has the potential to make individualized treatment of patients a reality. Merrimack's first commercial product, ONIVYDETM (irinotecan liposome injection), was approved by the U.S. FDA and with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, the Company is building one of the most robust oncology pipelines in the industry.

Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2000
Size (employees)
294 (est)
Merrimack Pharmaceuticals was founded in 2000 and is headquartered in Cambridge, US

Key People/Management at Merrimack Pharmaceuticals

Richard Peters

Richard Peters

President and Chief Executive Officer

Merrimack Pharmaceuticals Office Locations

Merrimack Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
1 Kendall Square

Merrimack Pharmaceuticals Financials and Metrics

Merrimack Pharmaceuticals Financials

Merrimack Pharmaceuticals's revenue was reported to be $144.3 m in FY, 2016
USD

Net income (Q2, 2017)

510.8 m

Market capitalization (13-Nov-2017)

157.5 m

Cash (30-Jun-2017)

135.5 m

EV

70.9 m
Merrimack Pharmaceuticals's current market capitalization is $157.5 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

47.8 m102.8 m89.3 m144.3 m

Revenue growth, %

115%(13%)62%

Cost of goods sold

6.9 m

Gross profit

137.4 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

21.3 m33.7 m28.1 m

Cost of goods sold

1.9 m1 m

Gross profit

31.8 m27.1 m

Gross profit Margin, %

94%96%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

65.1 m35.7 m185.6 m21.5 m

Accounts Receivable

5.9 m3.3 m6.5 m17.5 m

Inventories

5.5 m4.7 m5.5 m14.6 m

Current Assets

166.6 m132.1 m201.4 m57.4 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

105.5 m66.9 m77.8 m100.3 m28.8 m33.7 m56.4 m48.2 m21.5 m36.5 m17.2 m135.5 m

Accounts Receivable

8.8 m12.2 m6.6 m2.6 m4.2 m1.8 m2.1 m15.6 m19.3 m22.2 m43 k43 k

Inventories

8.1 m12.3 m14.8 m

Current Assets

200.3 m138.9 m103.8 m162.1 m99.3 m74.9 m70.9 m160.7 m119 m89.6 m46.3 m141.6 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(130.7 m)(83.6 m)(147.8 m)(153.5 m)

Depreciation and Amortization

2.6 m3.2 m4.3 m6.2 m

Accounts Receivable

3.4 m2.6 m(3.2 m)(11 m)

Inventories

4 m827 k(850 k)(9.7 m)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(39.8 m)(27.8 m)(18.3 m)(28 m)(34.4 m)(22.9 m)(42.4 m)(38.7 m)(51 m)(30.3 m)(30.2 m)

Accounts Receivable

6.6 m2.6 m4.2 m1.8 m2.1 m15.6 m19.3 m22.2 m43 k

Inventories

8.1 m12.3 m14.8 m
Show all financial metrics

Merrimack Pharmaceuticals Market Value History

Merrimack Pharmaceuticals Median Salaries

Source: 20 public H-1B filings from Merrimack Pharmaceuticals

Merrimack Pharmaceuticals's Web-traffic and Trends

Merrimack Pharmaceuticals Online and Social Media Presence

Merrimack Pharmaceuticals Company Life and Culture

You may also be interested in